Scarica l'app Stockscreener
240.48
0.34%
-0.83
Dopo l'orario di chiusura:
239.13
-1.35
-0.56%
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
Jazz Pharmaceuticals CEO Renee D. Gala Reports Share Sales and Tax Withholding on September 8, 2026 - Kalkine Media
Jazz Pharmaceuticals (NASDAQ: JAZZ) exec to sell restricted stock - Stock Titan
JAZZ: Record growth, new launches, and AI-driven strategies fuel rare disease expansion and raised outlook - TradingView
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace - Investing.com
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com UK
JAZZ Maintained by Barclays -- Price Target Raised to $271 - GuruFocus
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com India
Jazz Pharmaceuticals (JAZZ) Stock Looks Reasonable On Value While Returns Look Stretched - simplywall.st
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery By Investing.com - Investing.com Australia
JAZZ: Record revenue, pipeline expansion, and rare disease focus drive strong growth outlook - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Jazz Pharma (NASDAQ: JAZZ) exec plans $486K Rule 144 stock sale - Stock Titan
Jazz Pharmaceuticals (JAZZ) director moves to sell more stock - Stock Titan
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com Nigeria
Learn Why The Bull Case For Jazz Pharmaceuticals Stock Could Change Following FDA Drug Approval - simplywall.st
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Strong Buy Ratings and a 17.28% Upside Potential - DirectorsTalk Interviews
Jazz Pharmaceuticals Stock Price Forecast. Should You Buy JAZZ? - StockInvest.us
Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone? - Yahoo Finance
Four September conference talks will include Jazz Pharmaceuticals - Stock Titan
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report? - Yahoo Finance
Finance Watch: Multibillion-Dollar Debt Offerings Fuel Growth - insights.citeline.com
Jazz Pharmaceuticals PLC (JAZZ) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Why Jazz Pharmaceuticals (JAZZ) Is Down 6.3% After Ziihera’s First-Line HER2-Positive GEA Survival Data And What's Next - simplywall.st
Insider plans more Jazz (NASDAQ: JAZZ) share sales—but how big is this next trade? - stocktitan.net
JAZZ Rises on Updated OS Results From Gastric Cancer Study - Yahoo Finance
Canaccord reiterates Jazz Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Nigeria
Jazz reports Phase III trial interim results for Ziihera combination - clinicaltrialsarena.com
Jazz Pharmaceuticals Raises $1.25 Billion Via 1.875% Exchangeable Notes Due 2032 - TradingView
Jazz Pharmaceuticals (NASDAQ: JAZZ) director to sell 1,527 shares in 2026 - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) director to sell 3,507 shares - Stock Titan
No-Moat Jazz's Growth Supported by Strong Clinical Data for Ziihera and Expanding Opportunity - Morningstar
Jazz Pharma (NASDAQ: JAZZ) director to sell 3,507 shares in 2026 - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director plans $858K stock sale - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director may sell 3,507 shares - stocktitan.net
Jazz Pharmaceuticals (NASDAQ: JAZZ) director lines up 3,852-share sale for 2026 - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) director may sell 3,507 shares - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director to sell 3,507 shares - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director plans sale after 18,000 shares sold - Stock Titan
Positive Phase 3 Survival Results in HER2+ Advanced GEA – Jazz Pharmaceuticals - Oncodaily
Cancer drug decision could swing Jazz Pharmaceuticals' beatBizwomen - The Business Journals
JAZZ Looks 61.2% Overvalued on GF Value™ as Positive Trial Data Boosts Sentiment - GuruFocus
Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA - PR Newswire
Jazz Pharmaceuticals (JAZZ) Stock Analysis: A 17% Upside Potential Lights Up Investor Interest - DirectorsTalk Interviews
Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera - simplywall.st
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases - Finansavisen
Jazz Pharmaceuticals prices $1.1B exchangeable notes offering By Investing.com - Investing.com Nigeria
JAZZ PHARMACEUTICALS PLC : DEUTSCHE BANK RAISES TARGET PRICE TO $300 FROM $287 - webull.com
Jazz Pharmaceuticals plans $1 billion exchangeable notes offering By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals Plans $1 Billion Exchangeable Senior Notes Due 2032 - marketscreener.com
Jazz Pharmaceuticals plans $1 billion exchangeable notes offering - Investing.com
Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens - Sahm
Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA - Yahoo Finance
Jazz Pharmaceuticals stock rises after FDA approves Ziihera By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals stock hits all-time high at 265.54 USD By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals stock hits all-time high at 265.54 USD - Investing.com
Jazz Pharmaceuticals receives FDA approval for Ziihera HER2-positive GEA treatment - grafa.com
Jazz Pharma's fresh tune: New CEO wants to make longtime Bay Area drugmaker 'a true innovator' - The Business Journals
Advisors Preferred LLC Acquires New Shares in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals (JAZZ) As HER2 Pipeline Progress Fuels An Undervalued Narrative - simplywall.st
Great Lakes Advisors LLC Invests $8.15 Million in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals Announces $820 Million Acquisition of Actio Biosciences - Global Legal Chronicle
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jessica Merrill: Mid-Cap Biopharma's $1B-Plus Deal Surge Could Spawn the Next Amgen - finance.biggo.com
Jazz Pharmaceuticals (JAZZ) Stock Analysis: A Glimpse Into The 14.86% Potential Upside - DirectorsTalk Interviews
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):